Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tanvex, a Taiwan Biotech, Approved to Market Neupogen Biosimilar in the US

publication date: Jul 3, 2024

Taiwan’s Tanvex BioPharma was approved to launch a filgrastim biosimilar in the US to treat neutropenia induced by cancer chemotherapy. The originator drug is Amgen’s neupogen (filgrastim). TX01 is a recombinant human granulocyte colony-stimulating factor biologic that stimulates white blood cell production. The candidate, marketed as Nypozi, is the first Tanvex biosimilar approved for use in the US and the first biosimilar for any Taiwan biopharma. However, Nypozi is the fourth filgrastim biosimilar approved for US use, a market estimated to total $400 million per year. Tanvex was previously approved to sell the drug in Canada. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here